Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: Comparison with grapefruit juice

Clinical Pharmacology and Therapeutics

Volumn 73, Issue 6, 2003, Pages 529-537

  Bailey, David G ^a   Dresser, George K ^b   Bend, John R ^b  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 (2,3 DICHLOROPHENYL) 2,6 DIMETHYL 3,5 PYRIDINEDICARBOXYLIC ACID ETHYL METHYL ESTER; ALCOHOL; BERGAMOT OIL; CITRUS FRUIT EXTRACT; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; FELODIPINE; BERGAMOTTIN; CALCIUM CHANNEL BLOCKING AGENT; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PSORALEN DERIVATIVE; RADIOSENSITIZING AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HUMAN; HUMAN EXPERIMENT; LEMON JUICE; LINEAR SYSTEM; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; WINE; BEVERAGE; BIOTRANSFORMATION; CITRUS FRUIT; COMPARATIVE STUDY; DRUG INTERACTION; GRAPEFRUIT; HALF LIFE TIME; METABOLISM; MIDDLE AGED;

ADULT; AREA UNDER CURVE; BEVERAGES; BIOTRANSFORMATION; CALCIUM CHANNEL BLOCKERS; CITRUS; CITRUS PARADISI; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; FELODIPINE; FEMALE; FOOD-DRUG INTERACTIONS; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; NADP; PSORALENS; RADIATION-SENSITIZING AGENTS; WINE;

EID: 0037871830     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(03)00051-1     Document Type: Article

References (33)

1. Bailey DG, Spence JD, Munoz C, Arnold JMO. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991;337:268-9.
2. Bailey DG, Arnold JMO, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998;46:101-10.
3. Dresser GK, Bailey DG, Carruthers SG. Grapefruit juice-felodipine interaction in the elderly. Clin Pharmacol Ther 2000;68:28-34.
4. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997;99:2545-53.
5. Edwards DJ, Bellevue FH, Woster PM. Identification of 6′,7′-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos 1996;24: 1287-90.
6. Fukuda K, Ohta T, Oshima Y, Ohashi N, Yoshikawa M, Yamazoe Y. Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics 1997;7:391-6.
7. He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, Hollenberg PF. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 1998;11:252-9.
8. Guo L-Q, Fukuda K, Ohta T, Yamazoe Y. Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab Dispos 2000;28:766-71.
9. Bailey DG, Dresser GK, Kreeft JH, Munoz C, Freeman DJ, Bend JR. Grapefruit-felodipine interaction: effect of unprocessed fruit and probable active ingredients. Clin Pharmacol Ther 2000;68:468-77.
10. Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR. Grapefruit juice-felodipine interaction: effect of naringin and 6′,7′ -dihydroxybergamottin in humans. Clin Pharmacol Ther 1998;64:248-56.
11. Chan WK, Nguyen LT, Miller VP, Harris RZ. Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine. Life Sci 1998;62:PL135-42.
12. Offman EM, Freeman DJ, Dresser GK, Munoz C, Bend JR, Bailey DG. Red wine-cisapride interaction: comparison with grapefruit juice. Clin Pharmacol Ther 2001;70: 17-23.
13. Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther 2001;69:14-23.
14. Lee CA, Kadwell SH, Kost TA, Serabjit-Singh CJ. CYP3A4 expressed by insect cells infected with a recombinant baculovirus containing both CYP3A and human NADPH-cytochrome P450 reductase is catalytically similar to human liver microsomal CYP3A4. Arch Biochem Biophys 1995;319:157-67.
15. Ahnoff M. Determination of felodipine in plasma by capillary gas chromatography with electron capture detection. J Pharm Biomed Anal 1984;2:519-26.
16. Cummins CL, Jacobsen W, Benet LZ. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002;300:1036-45.
17. Edgar B, Regardh CG, Johnsson G, Johansson L, Lundborg P, Lofberg I, et al. Felodipine kinetics in healthy man. Clin Pharmacol Ther 1985;38:205-11.
18. Regardh CG, Baarnhielm C, Edgar B, Hoffman KJ. Pharmacokinetics and biotransformation of 1,4-dihydropyridine calcium antagonists. Prog Drug Metab 1990;12:41-86.
19. Guengerich FP, Brian WR, Iwasaki M, Sari MA, Baarnhielm C, Berntsson P. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P450IIIA4. J Med Chem 1991;34:1834-44.
20. Bailey DG, Bend JR, Arnold JMO, Tran LT, Spence JD. Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice. Clin Pharmacol Ther 1996;60:25-33.
21. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampicin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-8.
22. Lundahl J, Regardh CG, Edgar B, Johnsson G. Effects of grapefruit juice ingestion - pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol 1997; 52:139-45.
23. Blychert E, Edgar B, Elmfeldt D, Hedner T. A population study of the pharmacokinetics of felodipine. Br J Clin Pharmacol 1991;31:15-24.
24. Bailey DG, Arnold JMO, Bend JR, Tran LT, Spence JD. Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. Br J Clin Pharmacol 1995;40:135-40.
25. Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clin Pharmacokinet 1997;2:103-21.
26. Hendeles L, Wubbena P, Weinberger M. Food-induced dose dumping of one-a-day theophylline [letter]. Lancet 1984;2:1471 .
27. Hendeles L, Weinberger M, Milavetz G, Hill M III, Vaughan L. Food-induced "dose-dumping" from a one-a-day theophylline product as a cause of theophylline toxicity. Chest 1985;87:758-65.
28. Steffensen G, Pedersen S. Food induced changes in theophylline absorption from a once-a-day theophylline product. Br J Clin Pharmacol 1986;22:571-7.
29. Hendeles L, Weinberger M. Selection of a slow-release theophylline product. J Allergy Clin Immunol 1986;78: 743-51.
30. Pedersen S. Effects of food on the absorption of theophylline in children. J Allergy Clin Immunol 1986;78: 704-9.
31. Jonkman JH. Food interactions with sustained-release theophylline preparations. A review. Clin Pharmacokinet 1989;16:162-79.
32. Schug BS, Brendel E, Wonnemann M, Wolf D, Wargenau M, Dingler A, et al. Dosage form-related food interaction observed in a marketed once-daily nifedipine formulation after a high-fat American breakfast. Eur J Clin Pharmacol 2002;58:119-25.
33. Schug BS, Brendel E, Wonnemann M, Wolf D, Wargenau M, Dingler A, et al. Formulation-dependent food effects demonstrated for nifedipine modified-release preparations marketed in the European Union. Eur J Pharm Sci 2002;15:279-85.